Lecigon (Entacapone, Levodopa, Carbidopa Monohydrate)

Levodopa is a precursor that is converted to dopamine in the brain, restoring deficient neurotransmission. Carbidopa blocks peripheral decarboxylation of levodopa, allowing more to reach the central nervous system. Entacapone inhibits the COMT enzyme, reducing peripheral breakdown of levodopa and extending its duration of action.

The specific dose and dosing schedule of Lecigon are determined by the prescribing clinician based on the individual patient's disease severity, response to therapy, and tolerability. Patients should follow the prescriber’s instructions and not adjust the dose without medical guidance.

Safety data for Lecigon in pregnancy and lactation are limited. The product should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and this decision must be made by a qualified healthcare professional.

To place an order, submit an enquiry on the Lecigon product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Lecigon combines a COMT inhibitor (entacapone) with levodopa and carbidopa, offering longer and more stable levodopa plasma levels compared with levodopa/carbidopa alone. This can reduce OFF periods and improve motor control, whereas other classes such as dopamine agonists act on different receptors and may have distinct side‑effect profiles.

Lecigon tablets should be stored at ambient temperature, below 25 °C, in the original blister pack or container. Protect them from moisture, excessive heat and direct sunlight to maintain product stability throughout its shelf life.

Lecigon is taken orally, usually with food to reduce gastrointestinal irritation. The tablets are swallowed whole with a glass of water. The exact timing relative to meals and other Parkinson's medications should follow the prescribing clinician’s directions.

Serious adverse events include severe liver injury, neuroleptic malignant syndrome, marked hypotension, agranulocytosis and life‑threatening allergic reactions such as anaphylaxis. Patients should be monitored closely for any signs of these conditions and seek immediate medical attention if they occur.

Lecigon is contraindicated in individuals with known hypersensitivity to entacapone, levodopa, carbidopa or any excipients in the formulation. It should also be avoided in patients taking non‑selective MAO inhibitors or those with severe hepatic impairment unless specifically advised by a physician.